CRISPR Therapeutics $2.4 Billion Cash: Why the Stock Slump Persists
CRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Why Economic Indices Matter explains how these measurements influence asset allocation and risk controls, helping you make smarter financial decisions.
21,763 articlesCRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
A director sold 3,000 BlackLine shares in an open-market move. Here’s how to interpret that action, what it says abou...
A major tech partnership and improving chip demand helped Intel stock climb sharply on Thursday. This deep dive expla...
Despite renewed fatal-accident headlines, Tesla’s core growth story remains intact, with rising deliveries and softwa...
SpaceX embodies big dreams and bigger valuations. This piece digs into Morningstar's fair value for Spacex, why the m...
Political discussions around Social Security could reshape retirement planning. This article breaks down what the Spe...
Rocket Lab has unveiled a bold $8 billion move by announcing a plan to acquire Iridium. This article breaks down what...
Eli Lilly's blockbuster first quarter puts the spotlight on a possible stock split as its high-priced shares approach...
Income-focused investors face a tricky mood: chase reliable payouts or risk capital. Learn about three high-yield div...
A top Sea Limited executive sold a sizable stake, triggering questions about the stock's future. This guide breaks do...
Missed Sandisk's 580% rally? No worry. You can still ride the AI-driven chip surge with three smart stock picks, clea...
A recent CFO Form 4 shows a small share disposition at Synaptics while the company reports 10% revenue growth. This a...